Zelluna ASA [ZLNA]: The first ever cell therapy company to list on the Oslo Stock Exchange following successful completion of the business combination and private placement

Oslo, Norway, 03 March, 2025 - Zelluna ASA, a company pioneering allogeneic ‘off the shelf’ T Cell Receptor based Natural Killer (TCR-NK) cells for the treatment of cancer, today announces the successful completion of a Business Combination and Private Placement. All conditions for completion of the Business Combination have been met, including, confirmation by Euronext Oslo Børs of the continued listing, approval of the Prospectus and regulatory clearances.